Distribution of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors (VPAC1, VPAC2, and PAC1 receptor) in the rat brain

Journal of Comparative Neurology

Volumn 476, Issue 4, 2004, Pages 388-413

  Joo, Kyeung Min ^a   Chung, Yoon Hee ^b   Kim, Min Kyu ^a   Nam, Ryoung Hee ^a   Lee, Byung Lan ^a   Lee, Kyung Hoon ^c   Cha, Choong Ik ^a,d,e  

^a Seoul National University College of Medicine   (South Korea)

^b Chung Ang University   (South Korea)

^c Sungkyunkwan University   (South Korea)

^d Seoul National University   (South Korea)

^e Korea National Institute of Health   (South Korea)

Author keywords

Astrocytes; Double immunoflouorescence; Immunohistochemistry; Oligodendrocytes

Indexed keywords

HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR; RECEPTOR SUBTYPE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; ASTROCYTE; BRAIN; BRAIN CORTEX; BRAIN STEM; CEREBELLUM; HIPPOCAMPUS; HYPOTHALAMUS; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MALE; NEUROTRANSMISSION; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; RAT; THALAMUS; TISSUE DISTRIBUTION; WESTERN BLOTTING;

AGING; ANIMALS; BRAIN; IMMUNOHISTOCHEMISTRY; MALE; NEUROGLIA; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE, TYPE I; RECEPTORS, PITUITARY HORMONE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; TISSUE DISTRIBUTION; VASOACTIVE INTESTINAL PEPTIDE;

EID: 3543077645     PISSN: 00219967     EISSN: None     Source Type: Journal    
DOI: 10.1002/cne.20231     Document Type: Article

References (75)

1. Ashur-Fabian O, Giladi E, Brenneman DE, Gozes I. 1997. Identification of VIP/PACAP receptors on rat astrocytes using antisense oligodeoxynucleotides. J Mol Neurosci 9:211-222.
2. Basille M, Vaudry D, Coulouarn Y, Jegou S, Lihrmann I, Fournier A, Vaudry H, Gonzalez B. 2000. Comparative distribution of pituitary adenylate cyclase-activating polypeptide (PACAP) binding sites and PACAP receptor mRNAs in the rat brain during development. J Comp Neurol 425:495-509.
3. Besson J, Sarrieau A, Vial M, Marie JC, Rosselin G, Rostene W. 1986. Characterization and autoradiographic distribution of vasoactive intestinal peptide binding sites in the rat central nervous system. Brain Res 398:329-336.
4. Brenneman DE, Westbrook GL, Fitzgerald SP, Ennist DL, Elkins KL, Ruff MR, Pert CB. 1988. Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptide. Nature 335:639-642.
5. Brenneman DE, Hauser J, Phillips TM, Davidson A, Bassan M, Gozes I. 1999. Vasoactive intestinal peptide: link between electrical activity and glia-mediated neurotrophism. Ann N Y Acad Sci 897:17-26.
6. Burgunder JM, Heyberger B, Lauterburg T. 1999. Thalamic reticular nucleus parcellation delineated by VIP and TRH gene expression in the rat. J Chem Neuroanat 17:147-152.
7. Cai Y, Xin X, Shim GJ, Mokuno Y, Uehara H, Yamada T, Agui T, Matsumoto K. 1997. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) stimulate interleukin-6 production through the third subtype of PACAP/VIP receptor in rat bone marrow-derived stromal cells. Endocrinology 138:2515-2520.
8. Cazillis M, Gonzalez BJ, Billardon C, Lombet A, Fraichard A, Samarut J, Gressens P, Vaudry H, Rostene W. 2004. VIP and PACAP induce selective neuronal differentiation of mouse embryonic stem cells. Eur J Neurosci 19:798-808.
9. Chance WT, Thompson H, Thomas I, Fischer JE. 1995. Anorectic and neurochemical effects of pituitary adenylate cyclase activating polypeptide in rats. Peptides 16:1511-1516.
10. Chatterjee TK, Sharma RV, Fisher RA. 1996. Molecular cloning of a novel variant of the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor that stimulates calcium influx by activation of L-type calcium channels. J Biol Chem 271:32226-32232.
11. Chen D, Buchanan GF, Ding JM, Hannibal J, Gillette MU. 1999. Pituitary adenylyl cyclase-activating peptide: a pivotal modulator of glutamatergic regulation of the suprachiasmatic circadian clock. Proc Natl Acad Sci U S A 96:13468-13473.
12. Chihara K, Iwasaki J, Minamitani N, Kaji H, Matsukura S, Tamaki N, Matsumoto S, Fujita T. 1982. Effect of vasoactive intestinal polypeptide on growth hormone secretion in perfused acromegalic pituitary adenoma tissues. J Clin Endocrinol Metab 54:773-779.
13. Deutsch PJ, Schadlow VC, Barzilai N. 1993. 38-Amino-acid form of pituitary adenylate cyclase activating peptide induces process outgrowth in human neuroblastoma cells. J Neurosci Res 35:312-320.
14. Dow RC, Bennie J, Fink G. 1994. Pituitary adenylate cyclase-activating peptide-38 (PACAP)-38 is released into hypophysial portal blood in the normal male and female rat. J Endocrinol 142:R1-R4.
15. Ghandour MS, Langley OK, Vincendon G, Gombos G. 1979. Double labeling immunohistochemical technique provides evidence of the specificity of glial cell markers. J Histochem Cytochem 27:1634-1637.
16. Gonzalez BJ, Basille M, Vaudry D, Fournier A, Vaudry H. 1997. Pituitary adenylate cyclase-activating polypeptide promotes cell survival and neurite outgrowth in rat cerebellar neuroblasts. Neuroscience 78:419-430.
17. Gozes I, Bardea A, Reshef A, Zamostiano R, Zhukovsky S, Rubinraut S, Fridkin M, Brenneman DE. 1996. Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide. Proc Natl Acad Sci U S A 93:427-432.
18. Gozes I, Bachar M, Bardea A, Davidson A, Rubinraut S, Fridkin M, Giladi E. 1997. Protection against developmental retardation in apolipoprotein E-deficient mice by a fatty neuropeptide: implications for early treatment of Alzheimer's disease. J Neurobiol 33:329-342.
19. Gray SL, Cummings KJ, Jirik FR, Sherwood NM. 2001. Targeted disruption of the pituitary adenylate cyclase-activating polypeptide gene results in early postnatal death associated with dysfunction of lipid and carbohydrate metabolism. Mol Endocrinol 15:1739-1747.
20. Grimaldi M, Cavallaro S. 1999. Functional and molecular diversity of PACAP/VIP receptors in cortical neurons and type I astrocytes. Eur J Neurosci 11:2767-2772.
21. Haas HL, Gahwiler BH. 1992. Vasoactive intestinal polypeptide modulates neuronal excitability in hippocampal slices of the rat. Neuroscience 47:273-277.
22. Hannibal J. 2002. Pituitary adenylate cyclase-activating peptide in the rat central nervous system: an immunohistochemical and in situ hybridization study. J Comp Neurol 453:389-417.
23. Hannibal J, Jamen F, Nielsen HS, Journot L, Brabet P, Fahrenkrug J. 2001. Dissociation between light-induced phase shift of the circadian rhythm and clock gene expression in mice lacking the pituitary adenylate cyclase activating polypeptide type 1 receptor. J Neurosci 21:4883-4890.
24. Harmar AJ, Marston HM, Shen S, Spratt C, West KM, Sheward WJ, Morrison CF, Dorin JR, Piggins HD, Reubi JC, Kelly JS, Maywood ES, Hastings MH. 2002. The VPAC(2) receptor is essential for circadian function in the mouse suprachiasmatic nuclei. Cell 109:497-508.
25. Harmar T, Lutz E. 1994. Multiple receptors for PACAP and VIP. Trends Pharmacol Sci 15:97-99.
26. Hashimoto H, Ishihara T, Shigemoto R, Mori K, Nagata S. 1993. Molecular cloning and tissue distribution of a receptor for pituitary adenylate cyclase-activating polypeptide. Neuron 11:333-342.
27. Hashimoto H, Nogi H, Mori K, Ohishi H, Shigemoto R, Yamamoto K, Matsuda T, Mizuno N, Nagata S, Baba A. 1996. Distribution of the mRNA for a pituitary adenylate cyclase-activating polypeptide receptor in the rat brain: an in situ hybridization study. J Comp Neurol 371:567-577.
28. Ishihara T, Shigemoto R, Mori K, Takahashi K, Nagata S. 1992. Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron 8:811-819.
29. 1 receptor-deficient mice display impaired insulinotropic response to glucose and reduced glucose tolerance. J Clin Invest 105:1307-1315.
30. Kaiser PK, Lipton SK. 1990. VIP-mediated increase in cAMP prevents tetrodotoxin-induced retinal ganglion cell death in vitro. Neuron 5:373-381.
31. Karacay B, O'Dorisio MS, Kasow K, Hollenback C, Krahe R. 2001. Expression and fine mapping of murine vasoactive intestinal peptide receptor 1. J Mol Neurosci 17:311-324.
32. Koves K, Arimura A, Gorcs TG, Somogyvari-Vigh A. 1991. Comparative distribution of immunoreactive pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide in rat forebrain. Neuroendocrinology 54:159-169.
33. Lee M, Lelievre V, Zhao P, Torres M, Rodriguez W, Byun JY, Doshi S, Ioffe Y, Gupta G, de los Monteros AE, de Vellis J, Waschek J. 2001. Pituitary adenylyl cyclase-activating polypeptide stimulates DNA synthesis but delays maturation of oligodendrocyte progenitors. J Neurosci 21:3849-3859.
34. Lee SH, Cox CL. 2003. Vasoactive intestinal peptide selectively depolarizes thalamic relay neurons and attenuates intrathalamic rhythmic activity. J Neurophysiol (in press).
35. Lutz EM, Sheward WJ, West KM, Morrow JA, Fink G, Harmar AJ. 1993. The VIP2 receptor: molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide. FEBS Lett 334:3-8.
36. Masmoudi O, Gandolfo P, Leprince J, Vaudry D, Fournier A, Patte-Mensah C, Vaudry H, Tonon MC. 2003. Pituitary adenylate cyclase-activating polypeptide (PACAP) stimulates endozepine release from cultured rat astrocytes via a PKA-dependent mechanism. FASEB J 17:17-27.
37. Miyata A, Jiang LJ, Dahl RD, Kitada C, Kubo K, Fugino M, Minamino N, Arimura A. 1989. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 164:567-574.
38. Mizuno Y, Kondo K, Terashima Y, Arima H, Murase T, Oiso Y. 1998. Anorectic effect of pituitary adenylate cyclase activating polypeptide (PACAP) in rats: lack of evidence for involvement of hypothalamic neuropeptide gene expression. J Neuroendocrinol 10:611-616.
39. Offen D, Sherki Y, Melamed E, Fridkin M, Brenneman DE, Gozes I. 2000. Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease. Brain Res 854:257-262.
40. Ogawa-Meguro R, Itoh K, Mizuno N. 1992. Substance P-, vasoactive intestinal polypeptide-, and cholecystokinin-like immunoreactive fiber projections from the superior colliculus to the dorsal lateral geniculate nucleus in the rat. Exp Brain Res 89:59-66.
41. Ottesen B, Andersen AN, Gerstenberg T, Ulrichesen H, Manthorpe T, Fahrenkrug J. 1981. VIP stimulates prolactin release in women. Lancet 2:696.
42. Piggins HD, Antle MC, Rusak B. 1995. Neuropeptides phase shift the mammalian circadian pacemaker. J Neurosci 15:5612-5622.
43. Pisegna JR, Wank SA. 1993. Molecular cloning and functional expression of the pituitary adenylate cyclase-activating polypeptide type I receptor. Proc Natl Acad Sci U S A 90:6345-6349.
44. Rawlings SR, Hezareh M. 1996. Pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP/vasoactive intestinal polypeptide receptors: actions on the anterior pituitary gland. Endocr Rev 17:4-29.
45. Reed HE, Meyer-Spasche A, Cutler DJ, Coen CW, Piggins HD. 2001. Vasoactive intestinal polypeptide (VIP) phase-shifts the rat suprachiasmatic nucleus clock in vitro. Eur J Neurosci 13:839-843.
46. Roberto M, Scuri R, Brunelli M. 2001. Differential effects of PACAP-38 on synaptic responses in rat hippocampal CA1 region. Learn Mem 8:265-271.
47. Said SI. 2000. The Viktor Mutt Memorial Lecture. Protection by VIP and related peptides against cell death and tissue injury. Ann N Y Acad Sci 921:264-274.
48. Said SI, Mutt V. 1970. Polypeptide with broad biological activity: isolation from small intestine. Science 169:1217-1218.
49. Said SI, Porter JC. 1979. Vasoactive intestinal polypeptide release into hypophyseal portal blood. Life Sci 24:227-230.
50. Said SI, Dickman K, Dey RD, Bandyopadhyay A, De Stefanis P, Raza S, Pakbaz H, Berisha HI. 1998. Glutamate toxicity in the lung and neuronal cells: prevention or attenuation by VIP and PACAP. Ann N Y Acad Sci 865:226-237.
51. 1) performing on memory tasks. Brain Res Mol Brain Res 84:79-89.
52. Sawangjaroen K, Curlewis JD. 1994. Effects of pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal polypeptide (VIP) on prolactin, luteinizing hormone and growth hormone secretion in the ewe. J Neuroendocrinol 6:549-555.
53. Sherwood NM, Krueckl SL, McRory JE. 2000. The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/ glucagons superfamily. Endocr Rev 21:619-670.
54. Sheward WJ, Lutz EM, Harmar AJ. 1995. The distribution of vasoactive intestinal peptide2 receptor messenger RNA in the rat brain and pituitary gland as assessed by in situ hybridization. Neuroscience 67:409-418.
55. Shin CM, Chung YH, Kim MJ, Lee EY, Kim EG, Cha CI. 2002. Age-related changes in the distribution of nitrotyrosine in the cerebral cortex and hippocampus of rats. Brain Res 931:194-199.
56. Shioda S, Shuto Y, Somogyvari-Vigh A, Legradi G, Onda H, Coy DH, Nakajo S, Arimura A. 1997. Localization and gene expression of the receptor for pituitary adenylate cyclase-activating polypeptide in the rat brain. Neurosci Res 28:345-354.
57. Spengler D, Waeber C, Pantaloni C, Holsboer F, Bockaert J, Seeburg PH, Journot L. 1993. Differential signal transduction by five splice variants of the PACAP receptor. Nature 9:170-175.
58. Sreedharan SP, Patel DR, Huang JX, Goetzl EJ. 1993. Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor. Biochem Biophys Res Commun 193:546-553.
59. Sun QQ, Prince DA, Huguenard JR. 2003. Vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide activate hyperpolarization-activated cationic current and depolarize thalamo-cortical neurons in vitro. J Neurosci 23:2751-2758.
60. Swanson LW. 1998. Brain maps: structure of the rat brain. Amsterdam: Elsevier.
61. Takatsuji K, Tohyama M. 1989. The organization of the rat lateral geniculate body by immunohistochemical analysis of neuroactive substances. Brain Res 480:198-209.
62. Takei N, Torres E, Yuhara A, Jongsma H, Otto C, Korhonen L, Abiru Y, Skoglosa Y, Schutz G, Hatanaka H, Sofroniew MV, Lindholm D. 2000. Pituitary adenylate cyclase-activating polypeptide promotes the survival of basal forebrain cholinergic neurons in vitro and in vivo: comparison with effects of nerve growth factor. Eur J Neurosci 12:2273-2280.
63. Tanaka S, Koike T. 1994. Vasoactive intestinal peptide suppresses neuronal cell death induced by nerve growth factor deprivation in rat sympathetic ganglion cells in vitro. Neuropeptides 26:103-111.
64. Usdin TB, Bonner TI, Mezey E. 1994. Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology 135:2662-2680.
65. Vaudry D, Gonzalez BJ, Basille M, Anouar Y, Fournier A, Vaudry H. 1998. Pituitary adenylate cyclase-activating polypeptide stimulates both c-fos gene expression and cell survival in rat cerebellar granule neurons through activation of the protein kinase A pathway. Neuroscience 84:801-812.
66. Vaudry D, Gonzalez BJ, Basille M, Fournier A, Vaudry H. 1999. Neurotrophic activity of pituitary adenylate cyclase-activating polypeptide on rat cerebellar cortex during development. Proc Natl Acad Sci U S A 96:9415-9420.
67. Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, Vaudry H. 2000. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev 52:269-324.
68. Vaudry D, Pamantung TF, Basille M, Rousselle C, Fournier A, Vaudry H, Beauvillain JC, Gonzalez BJ. 2002a. PACAP protects cerebellar granule neurons against oxidative stress-induced apoptosis. Eur J Neurosci 15:1451-1460.
69. Vaudry D, Rousselle C, Basille M, Falluel-Morel A, Pamantung TF, Fontaine M, Fournier A, Vaudry H, Gonzalez BJ. 2002b. Pituitary adenylate cyclase-activating polypeptide protects rat cerebellar granule neurons against ethanol-induced apoptotic cell death. Proc Natl Acad Sci U S A 99:6398-6403.
70. Vaudry D, Falluel-Morel A, Basille M, Pamantung TF, Fontaine M, Fournier A, Vaudry H, Gonzalez BJ. 2003. Pituitary adenylate cyclase-activating polypeptide prevents C2-ceramide-induced apoptosis of cerebellar granule cells. J Neurosci Res 72:303-316.
71. Vertongeri P, Schiffmann SN, Gourlet P, Robberecht P. 1997. Autoradiographic visualization of the receptor subclasses for vasoactive intestinal polypeptide (VIP) in rat brain. Peptides 18:1547-1554.
72. Wang HL, Li A, Wu T. 1997. Vasoactive intestinal polypeptide enhances the GABAergic synaptic transmission in cultured hippocampal neurons. Brain Res 746:294-300.
73. Wiemelt AP, Lehtinen M, McMorris FA. 2001. Agonists calcitonin, corticotropin-releasing hormone, and vasoactive intestinal peptide, but not prostaglandins or beta-adrenergic agonists, elevate cyclic adenosine monophosphate levels in oligodendroglial cells. J Neurosci Res 65:165-172.
74. 1-R) is expressed on gastric ECL cells: evidence by immunocytochemistry and RT-PCR. Ann N Y Acad Sci 865:147-156.
75. Zhang QL, Liu J, Lin PX, Webster H. 2002. Local administration of vasoactive intestinal peptide after nerve transection accelerates early myelination and growth of regenerating axons. J Peripher Nerv Syst 7:118-127.